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Abstract
Conventional cytotoxic chemotherapy is highly effective in certain cancers, but causes dose-
limiting damage to normal proliferating cells, especially hematopoietic stem and progenitor cells 
(HSPCs). Serial exposure to cytotoxics causes a long-term hematopoietic compromise 
(‘exhaustion’), which limits the use of chemotherapy and success of cancer therapy. Here, we 
show that the co-administration of G1T28 (trilaciclib), a small-molecule inhibitor of cyclin-
dependent kinases 4 and 6 (CDK4/6), contemporaneously with cytotoxic chemotherapy protects 
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murine hematopoietic stem cells (HSCs) from chemotherapy-induced exhaustion in a serial 5-
fluorouracil (5FU) treatment model. Consistent with a cell intrinsic effect, we show directly 
preserved HSC function resulting in a more rapid recovery of peripheral blood counts, enhanced 
serial transplantation capacity and reduced myeloid skewing. When administered to healthy 
human volunteers, G1T28 demonstrated excellent in vivo pharmacology and transiently inhibited 
bone marrow (BM) HSPC proliferation. These findings suggest that the combination of CDK4/6 
inhibitors (CDK4/6i) with cytotoxic chemotherapy should provide a means to attenuate therapy-
induced BM exhaustion in patients with cancer.
INTRODUCTION
Human BM is sensitive to cell cycle dependent cytotoxic agents, and myelosuppression is 
the dose-limiting toxicity for most such agents. Myelosuppression causes life-threatening 
morbidity, augments the cost of care, and compromises therapeutic efficacy, through the 
induction of treatment delays and reduced therapeutic intensity. It has further been suggested 
that cytotoxic chemotherapy induces lasting immunosuppression that dampens a beneficial 
anti-tumor immune response (1). The long-term BM toxicity of cytotoxics is also a major 
problem for cancer survivors, because it is associated with serious late toxicities of cancer 
therapy: BM exhaustion, myelodysplastic syndrome (MDS), and acute leukemia. Whereas 
the depletion of committed hematopoietic progenitor cells (HPCs) is largely responsible for 
the acute hematopoietic toxicity of chemotherapy, damage and functional attrition of HSCs 
contribute to therapy-induced late myelotoxicity (2–5).
Existing strategies to manage chemotherapy-induced myelosuppression focus on correcting 
acute cytopenias through the transfusion of platelets and red cells, and the administration of 
growth factors: granulocyte-colony stimulating factor (G-CSF) or erythropoietin (EPO). 
Transfusions decrease quality of life during therapy and are associated with transfusion 
reactions and risk of infection. Although growth factors ameliorate acute myelosuppression, 
their use is problematic in that they have substantial acute toxicity of their own (for example, 
excess mortality and thrombosis for EPO, fever and bone pain for G-CSF) and adverse long-
term consequences manifesting as exacerbated HSC exhaustion (6, 7) and an increased risk 
for MDS and leukemia (8, 9). To date, no therapeutic option is available to prevent or treat 
chemotherapy-induced functional exhaustion of HSCs.
It has long been suggested that selective inhibition of the proliferation of normal but not 
cancer cells may provide protection from chemotherapy-induced toxicity (10, 11), but an 
incomplete understanding of cell cycle regulation has prevented the reduction of this concept 
to practice. We and others have shown that HSPCs depend on CDK4/6 activity for 
proliferation (12–14), whereas many human cancers are resistant to CDK4/6 inhibition (for 
example retinoblastoma (RB)-deficient cancers) (15, 16). This suggests that co-
administration of a CDK4/6 inhibitor (CDK4/6i) with cytotoxic chemotherapeutic agents 
could augment the therapeutic window by protecting normal HSPCs without negating the 
anti-neoplastic effect against CDK4/6-independent tumors. Using a long-acting oral 
CDK4/6i, we previously showed that a transient period of “pharmacological quiescence” 
(PQ) can reduce platinum chemotherapy-induced acute myelosuppression in vivo (17). It is 
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unclear, however, whether long-term BM toxicities of chemotherapy can be attenuated by 
PQ.
G1T28 (trilaciclib) is a small-molecule CDK4/6i developed for reducing chemotherapy-
induced myelosuppression (18). This molecule affords excellent in vivo protection against 
DNA-damaging agents in rodent models and has favorable potency, selectivity, and 
pharmacological properties for this purpose (18). In particular, G1T28 is well-suited for 
chemoprotection applications, which require an agent with a short biological half-life and 
intravenous (IV) formulation. In this study, we examine the ability of G1T28 to modulate 
HSPC proliferation and preserve long-term HSC function in humans and mice.
RESULTS
G1T28 induces transient and reversible G1 cell cycle arrest in murine HSPCs
We first determined the pharmacodynamic response of murine HSPCs to G1T28 using 5-
ethynyl-2′-deoxyuridine (EdU) incorporation assay (fig. S1–4), focusing on dose and 
schedule. A single intraperitoneal (IP) dose of G1T28 was sufficient to induce a dose-
dependent reduction in EdU incorporation (S-phase cells) in all hematopoietic cell types at 
12 hours after treatment (Fig. 1A–C, fig. S2 and S3), without causing other cell cycle effects 
such as G2/M arrest (fig. S2) or acute cytotoxicity (fig. S4C). This G1T28-induced reduction 
in S-phase cell frequency was independently confirmed using DNA content analysis (fig. 
S3B and S4B). HSCs, early HPCs (LSK cells and myeloid progenitors [MPs]), and 
developing lymphoid cells were the most sensitive to CDK4/6i-induced G1 arrest, showing a 
significantly lower ED50 (Fig. 1B, p < 0.001) for G1T28 and a more complete G1 cell cycle 
arrest (Fig. 1C, p < 0.05) compared to maturing erythroid and myeloid cells.
The cell cycle arrest induced by G1T28 was transient, reversible, and dose-related (Fig. 1A–
D, fig. S3, and fig. S4B,D–J). In HSCs, a reduction in EdU incorporation and S/G2/M cell 
frequency was seen as early as 4 hours after G1T28 treatment, reaching a minimum at 12 
hours, and lasting up to 36 hours before recovery (Fig. 1D and S4B). Doses of G1T28 above 
50 mg/kg did not cause a further reduction in EdU incorporation (Fig. 1A, fig. S3C–I), but 
rather extended the duration of cell cycle arrest (Fig. 1D and fig. S4B,D–J), consistent with 
the measured pharmacokinetics (PK) of G1T28 in mice (fig. S5). Of note, CDK4/6 
inhibition not only reduced homeostatic proliferation of HSCs (Fig. 1A, D; S3B and S4B), 
but also abrogated the potent cell cycle entry of HSCs seen during recovery from cytotoxic 
myeloablation (fig. S3J), which is essential for maintaining HSC cell cycle arrest during 
prolonged chemotherapy treatment.
The duration of the G1T28-induced cell cycle arrest differed by hematopoietic cell types, 
correlating inversely with the sensitivity of each cell type to CDK4/6 inhibition: T cells > 
HSPCs >= B cells > maturing myeloid and erythroid cells (Fig. 1D and S4D–J). Notably, the 
proliferation rates of most hematopoietic cell types increased beyond steady state during the 
early period of recovery (Fig. 1D and fig. S4B,E–J), likely reflecting compensatory 
proliferation in response to the transient mild reduction of BM cellularity as a result of 
HSPC cell cycle arrest (fig. S4C).
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G1T28 also induces a transient, reversible G1 arrest of human HSPCs
To determine whether G1T28 can induce a similar transient and reversible G1 cell cycle 
arrest in human HSPCs, as well as to characterize the pharmacological properties and safety 
of the compound, we completed a first-in-human Phase I clinical trial in healthy volunteers. 
In total, 45 subjects were enrolled; 36 received G1T28 in seven dosing groups and nine 
received placebo. On average, demographic characteristics (table S1) were comparable 
among the seven G1T28 groups and the placebo group with regard to mean age, body mass 
index (BMI), and body surface area (BSA). G1T28 and placebo (5% dextrose solution) were 
administered as a 30-minute IV infusion. Of the 33 subjects enrolled in the single ascending 
dose (SAD) part of the study, 24 received G1T28 at doses of 6, 12, 24, 48, 96, or 192 mg/m2 
and 9 subjects received placebo (table S2). Overall, a single IV infusion of G1T28 at all test 
doses was well tolerated. The most frequently reported treatment emergent adverse events 
(TEAEs) were headache and nausea (table S3). No TEAEs of severe or life-threatening 
intensity were reported, and all moderate TEAEs spontaneously resolved within 24 hours. 
There were no clinically relevant changes in any of the treatment groups with respect to 
clinical laboratory testing (clinical chemistry, hematology [blood cell counts, including 
absolute reticulocyte and banded neutrophil counts], and urinalysis), vital signs, ECG, 
physical examination, or body weight.
The pharmacokinetic properties of G1T28 were assessed using standard approaches. After a 
single IV infusion of G1T28 at doses shown in table S2, the median time (tmax) to reach 
peak serum concentration (Cmax) ranged between 0.25 and 0.47 h after start of infusion (Fig. 
1E and table S4). The geometric mean of Cmax and the estimated area under the curve 
(AUC0-t and AUC0-inf) for G1T28 increased in a dose-proportional manner over the dose 
ranges tested (table S4). The elimination of G1T28 appeared to occur in 3 phases after the 
end of infusion (EOI): a fast α-phase until approximately 4 h, followed by a β-phase until 
approximately 36 h, and a more gradual terminal γ-phase, suggesting a 3‐compartment 
model (Fig. 1E). Because the concentrations of the lowest dose groups fell below the 
quantifiable limit before the last elimination phase, the terminal half-life (t1/2) of the lowest 
dose groups was determined by the first elimination phase (t1/2 of 5.32 to 9.28 h). The 
terminal t1/2 of the 48, 96, and 192 mg/m2 dose groups was determined by the second 
elimination phase, with a t1/2 of 12.9 to 14.7 h (table S4). However, because the contribution 
of the terminal phase to the effective half‐life of the drug is approximately 15-20%, the 
longer t1/2 at the higher dose levels is likely to be less relevant. Compartmental analysis at 
the biologically effective dose (BED) of 192 mg/m2 demonstrated geometric mean values 
for Cmax and AUC0-inf of 1705 ng/mL and 2991 h*ng/mL, respectively (table S4). The 
coefficients of variability (%) for these values were all ≤ 15%, demonstrating low inter‐
subject variability. Total systemic exposure was independent of gender, body surface area, 
age, and body weight. These results demonstrate that G1T28 has acceptable in vivo 
pharmacology for use in human patients.
To determine the effects of G1T28 on human HSPC proliferation, we analyzed the cell cycle 
status of BM HSPCs in 12 subjects (cohort 7) either before or after G1T28 treatment (BED, 
192 mg/m2). A single BM aspirate was obtained from each subject (before dose, n = 5; 24 h, 
n = 3; 32 h, n = 4), and cell cycle status of total BM, uncommitted BM HSPCs, and lineage-
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committed BM cells were assessed by cellular DNA content analysis (table S5, fig. S6 and 
S7). Total BM cells showed a 45% reduction in S/G2/M cell frequency at 24 hours with a 
partial recovery at 32 hours (Fig. 1F). This extent of G1T28-induced total BM cell cycle 
arrest is in line with murine data (fig. S4D). The effects of G1T28 on the proliferation of 
different BM cell lineages were also consistent with the murine findings. The percentage of 
cells in S/G2/M phase of the cell cycle decreased at 24 hours after G1T28 for all cell 
populations except the granulocyte lineage (Fig. 1G, fig. S7, and table S5). As in the mouse, 
the strongest effects were seen on immature HSPCs, with more modest effects on 
differentiated cells (fig. S7 and table S5). Given that a single dose of G1T28 did not 
significantly alter peripheral blood (PB) cell counts for up to 14 days after infusion (fig. S8), 
these data together suggest G1T28-induced HSPC cell cycle arrest is transient and 
reversible, and well-tolerated in humans.
Transient G1 arrest accelerates hematologic recovery after single dose 5FU treatment
We next examined the effects of a transient HSPC G1 arrest on chemotherapy-induced BM 
exhaustion using 5FU, a pyrimidine analogue toxic to proliferating cells (19). Although a 
single dose of 5FU causes transient myelosuppression without directly damaging quiescent 
HSCs (20), repeated doses of 5FU provide a well-characterized model of HSC exhaustion 
(21, 22). First, to determine the effects of PQ on 5FU-induced acute myelosuppression, adult 
C57BL/6 mice were treated with either vehicle or G1T28 30 minutes before a single 
injection of 5FU. 5FU treatment caused a rapid and transient depletion of all blood cell 
lineages (Fig. 2A). In accord with published studies (17), G1T28 pre-treatment did not 
prevent the initial drop in blood cell counts, but significantly accelerated the PB count 
recovery (Fig. 2A, p < 0.05). Because the acute hematologic toxicity of 5FU is caused by the 
depletion of rapidly dividing HPCs (18, 20), we determined the effect of G1T28 treatment 
on the number of BM progenitors at various time points after 5FU administration using the 
methylcellulose colony formation assay. Although G1T28 treatment did not prevent the 
decline of total BM cell count at 24 hours after 5FU administration (Fig. 2B), it increased 
the number of colony-forming cells that survived 1 and 2 days after 5FU treatment (Fig. 2C), 
resulting in a faster recovery of the number of colony-forming progenitors (Fig. 2C) and an 
accelerated recovery of BM cell counts (Fig. 2B). Together, these data indicate that a 
G1T28-induced transient G1 cell cycle arrest attenuates the acute hematopoietic toxicity of 
cytotoxic agents by protecting rapidly proliferating BM progenitors.
Transient G1 cell cycle arrest protects mice from repeated 5FU-induced lethal 
myelosuppression
Single-dose 5FU treatment causes transient myelosuppression, but repeated administration 
of 5FU at relatively short intervals (7–10 days) causes irreversible morbidity requiring 
euthanasia, resulting from incomplete recovery of BM hematopoiesis between treatments 
(23–25). To determine whether PQ at the time of each serial dose of 5FU could afford 
survival protection, we subjected adult mice to repeated doses of 5FU at intervals of 7 or 10 
days. Twelve hours before (−12 h) each 5FU injection, animals received either vehicle, or 50 
or 100 mg/kg of G1T28. In all cases, G1T28-treated animals exhibited a marked and dose-
dependent enhancement in survival compared to vehicle-treated controls (Fig. 3A, B). At the 
100 mg/kg dose, G1T28-treated mice showed a 55% increase in median survival over 
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controls (28 days vs. 18 days) when 5FU was given at 7-day intervals (Fig. 3A), and a 125% 
increase in median survival (63 days vs. 28 days) when 5FU was given at 10-day intervals 
(Fig. 3B). Marked protection was also noted in the 10-day assay when G1T28 was given 30 
minutes (−30 min) before each 5FU treatment, but not when it was given 24 hours (−24 h) 
before 5FU treatment (Fig. 3C). G1T28 given twice, at −24 h and −30 min, offered no 
additional protection over treatment at −30 min alone (Fig. 3C). After intraperitoneal 
injection, 5FU is rapidly eliminated from the plasma (t1/2 = 10-20 minutes) (26) and then 
induces DNA damage for several hours post-infusion. Given that the maximum G1 arrest in 
HSPCs occurs between 12 and 24 hours after G1T28 treatment (Fig. 1D and fig. S4B, D–J), 
the finding of enhanced protection when G1T28 was administered at −30 minutes or −12 
hours, but not −24 hours, suggests that potent protection of HSPCs is best achieved when the 
period of G1 arrest overlaps with the in vivo biologic effect of 5FU treatment. Other 
structurally distinct CDK4/6 inhibitors (palbociclib and ribociclib), as well as G-CSF 
(pegfilgrastim), also demonstrated a survival benefit in this assay (Fig. 3D, table S6). These 
results suggest that a CDK4/6i-induced G1 cell cycle arrest provides a substantial reduction 
in lethal myelosuppression caused by serial administration of a cytotoxic agent.
Transient G1 arrest by G1T28 at the time of chemotherapy protects murine HSCs from 
serial 5FU treatment-induced proliferative exhaustion
Even in the absence of direct cytotoxicity, chemotherapy agents can induce functional 
attrition of HSCs through a process of proliferative exhaustion. HSCs have an extensive but 
finite capacity to sustain multilineage hematopoiesis (27), and repeated rounds of 
proliferation (such as during recovery from 5FU-induced BM ablation) readily exhaust their 
long-term multilineage reconstitution potential. To determine whether the attenuation of 
acute chemotherapy-induced myelosuppression by transient G1 arrest (Fig. 2) can reduce the 
proliferative burden on quiescent HSCs, thereby extending their functional lifespan, we 
assessed the effect of G1T28 on protecting HSCs against serial 5FU treatment-induced 
proliferative exhaustion. Young adult B6.SJL (CD45.1+) mice were treated with 4 rounds of 
5FU +/− G1T28 at 3-week intervals (Fig. 4A) - a schedule that causes HSC proliferative 
exhaustion and premature aging (22). As was the case after a single dose of 5FU (Fig. 2A), 
complete blood count (CBC) analysis after the fourth serial dose of 5FU showed that the 
G1T28-treated mice exhibited faster count recovery compared to vehicle-treated controls 
(fig. S9A). After 4 rounds of 5FU followed by count recovery, BM cells were harvested, 
enumerated, and transplanted as per Fig. 4A. Consistent with a previous report (22), serial 
5FU treatment caused a decrease in BM B cell frequency and an increase in BM HSC 
frequency, similar to those observed during hematopoietic aging (28–31), which were not 
rescued by G1T28 pre-treatment (fig. S9B, C). These observations suggest that although a 
transient G1 arrest at the time of 5FU administration affords potent protection of PB counts 
after each cycle, it does not rescue the aging-like phenotypic expansion of HSCs induced by 
serial 5FU.
To directly test whether a transient G1 arrest at the time of each dose of serial 5FU protects 
long-term HSC function, we performed competitive BM transplantation assays 8 weeks after 
the last dose of 5FU (Fig. 4A). Five hundred thousand BM cells (CD45.1+) harvested from 
5FU-only or 5FU+G1T28 treated mice were transplanted against an equal number of 
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untreated CD45.2+ BM cells into lethally irradiated C57BL/6 recipients (CD45.2+). The 
frequencies of donor-derived cells in recipient PB were monitored monthly for 4 months 
after transplant. Although serial 5FU treatment significantly reduced the long-term 
contribution of HSCs to all PB lineages (Fig. 4B–E, p < 0.05), HSCs from G1T28-treated 
animals demonstrated enhanced reconstitution of all lineages (Fig. 4B–E, p < 0.05). This 
observation indicates that a transient G1 arrest induced contemporaneously with serial 
administration of 5-FU provides a sustained, transplantable attenuation of chemotherapy-
induced HSC damage.
Given that growth factor treatment is currently used to address chemotherapy-induced 
myelosuppression, we also directly compared the effects of G-CSF (pegfilgrastim) treatment 
with G1T28-induced G1 arrest on protecting long-term HSC function from serial 5FU-
induced damage. Whereas pegfilgrastim enhanced survival against serial 5FU treatment at 
short intervals, presumably by stimulating the proliferation of surviving myeloid progenitors 
(Fig. 3D and table S6), pegfilgrastim treatment 24 and 48 hours after each cycle of 5FU 
treatment did not benefit long-term HSC function. In fact, G-CSF treatment further reduced 
the long-term multilineage reconstitution potential of HSCs compared to 5FU treatment 
alone (Fig. 4B–E). Moreover, the combined use of pegfilgrastim with G1T28 abolished the 
HSC protective effect of G1T28 (Fig. 4B–E). These data are in line with previous reports 
that G-CSF treatment exacerbates HSC injury after irradiation (32, 33) and findings that its 
use is associated with an increased later risk of myelodysplasia or leukemia (8, 9) . 
Therefore, although G-CSF can accelerate the acute hematologic recovery after BM injury, it 
appears to also exacerbate HSC exhaustion (7), likely due to disrupting HSC-niche 
interaction that results in HSC mobilization and proliferation (34). In contrast, the PQ 
approach by CDK4/6i appears to benefit both acute count recovery and long-term HSC 
function.
An analysis of the BM of recipient mice at 32 weeks after transplantation showed that 
G1T28 pre-treatment also increased donor cell reconstitution of all lineages in the BM 
compared to 5FU treatment alone (Fig. 4F). Analogous to transplantation studies comparing 
murine HSCs from young and old donors (31, 35, 36), the frequency of donor-derived HSCs 
in recipient BM was not reduced by 5FU treatment, regardless of G1T28 administration 
(Fig. 4F). These findings indicate that a period of G1 arrest bracketing the time of each 5FU 
treatment rescues HSC exhaustion—a decline in HSC function on a per cell basis that is 
induced by serial exposure to chemotherapy or aging.
To determine the durability of HSC protection afforded by G1T28-induced G1 arrest, we 
transplanted 107 total BM cells from each primary recipient into lethally irradiated 
individual secondary recipient mice 32 weeks after the initial transplantation. HSCs from 
G1T28-treated mice continued to produce significantly greater overall reconstitution in the 
secondary recipients (Fig. 5A, p < 0.05). Of note, although 5FU-only treated BM cells 
contributed poorly to PB lymphoid cells in secondary recipients (Fig. 5A), consistent with 
the myeloid-skewed differentiation pattern of aged or exhausted HSCs (31, 37), G1T28-
pretreated cells maintained robust lymphoid reconstitution potential (Fig. 5A). Accordingly, 
when a separate group of 5FU ± G1T28 treated mice were analyzed 13 months after the 
fourth dose of 5FU, in the absence of BM transplantation, G1T28-pretreated mice also 
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showed a significantly higher PB lymphoid to myeloid cell ratio compared to 5FU-only 
treated mice (fig. S9D, p < 0.05). We carefully monitored our colonies for malignancy after 
primary and secondary transplantation, but did not observe the emergence of secondary 
hematologic malignancies in any 5FU +/− G1T28 treated mice or BM transplant recipients 
during a 1-year follow-up period. Together, these results indicate that PQ at the time of serial 
5FU treatment protects the long-term reconstitution potential of HSCs and attenuates the 
myeloid-biased differentiation of damaged or aged HSCs.
G1T28-induced G1 arrest protects long-term HSC function against serial 5FU treatment by 
reducing HSC proliferative burden
To directly demonstrate that transient G1 arrest attenuates HSC exhaustion through a 
reduction in proliferative burden, we analyzed the proliferative history of individual HSCs 
after a single dose of 5FU with or without G1T28 pre-treatment using the histone H2B-
green fluorescent protein (H2B-GFP) label dilution assay (38, 39). In this assay, the 
replicative history of an individual HSC can be inferred by measuring the dilution of GFP-
tagged histones, which are conditionally expressed under the control of a doxycycline-
inducible promoter. Specifically, adult H2B-GFP;M2-rtTA double transgenic mice were 
treated with doxycycline for 6 weeks to label all HSCs with H2B-GFP (39). Two weeks after 
doxycycline removal, mice received vehicle, G1T28, 5FU, or 5FU+G1T28 (with G1T28 
given 12 hours before 5FU). H2B-GFP expression in BM HSCs was quantified 4 weeks 
after 5FU treatment, allowing time for complete hematologic recovery. In mice that received 
vehicle only, BM HSCs divided 2.1 ± 0.4 times on average, generating 4.3 ± 2.1 daughter 
HSCs (or a proliferation index [PI] = 4.3 ± 2.1) over the 6 weeks after doxycycline removal 
(Fig. 5B). G1T28 treatment alone did not affect HSC proliferation over the same period of 
time (2.4 ± 1.0 divisions, PI = 6.2 ± 2.6) (Fig. 5B, C). In contrast, a single injection of 5FU 
greatly increased HSC proliferation (5.3 ± 0.5 divisions, PI = 41.3 ± 5.4), which was 
partially rescued by G1T28 pre-treatment (4.6 ± 0.4 divisions, PI = 25.2 ± 4.7) (Fig. 5B, C). 
Of note, this benefit was observed after only a single round of 5FU. We were unable to 
assess the entire proliferation history of individual HSCs after 4 rounds of 5FU treatment 
because of detection limitations of the H2B-GFP label dilution assay, but we expect that the 
benefit of PQ would be cumulative with additional cycles. Therefore, PQ at the time of 5FU 
treatment appears to attenuate HSC exhaustion, at least in part by reducing the number of 
proliferative events inflicted on an HSC by each round of chemotherapy.
DISCUSSION
In this work, we have shown that G1T28, a potent and selective CDK4/6i, can induce a 
specific and transient G1 cell cycle inhibition in HSPCs, particularly HSCs. In accord with 
prior work (17, 18), a transient G1 arrest induced by contemporaneous administration of this 
CDK4/6i at the time of chemotherapy can markedly ameliorate the acute hematopoietic 
toxicity of cytotoxic chemotherapy. Of note, we showed that in addition to a beneficial effect 
on rapidly proliferating hematopoietic progenitors, PQ can also provide lasting protection of 
the per cell function of quiescent HSCs, thereby ameliorating the long-term toxicity 
associated with serial exposure to chemotherapy agents (‘exhaustion’).
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We also describe first-in-human results of G1T28 in a Phase I trial in healthy volunteers, 
showing that G1T28 has minimal toxicity and excellent PK and induces a strong 
proliferative arrest of early human HSPCs. G1T28 is well tolerated after a single IV infusion 
and has robust pharmacodynamic activity in the BM. At the BED of 192 mg/m2, BM HSPCs 
exhibited robust G1 cell cycle arrest at 24 and 32 hours after treatment, which should be a 
sufficient length of time to maintain HSPC quiescence when co-administered with 
chemotherapy. Standard of care chemotherapy for small cell lung cancer (SCLC) includes 
carboplatin and etoposide in the first line setting and single agent topotecan in the 2nd/3rd-
line. Terminal half-lives for these agents are 6, 7.5, and 3 hours, respectively. Based on these 
half-lives, a 32-hour G1 arrest would allow approximately 94% (4 half-lives) of the 
etoposide to be cleared and even more for the other agents. The desired characteristics for a 
CDK4/6i used for chemoprotection differ from those developed as antineoplastic agents, 
where typical properties tend to include a longer biological half-life that supports single 
daily dosing, large volume of distribution, accumulation on repeated dosing, and oral 
delivery. As expected, considering the dependence of early HSPCs on CDK4/6 for 
proliferation, continued daily administration of antineoplastic CDK4/6 inhibitors is 
associated with myelosuppression, particularly neutropenia (40, 41). It is believed that this is 
not a cytotoxic effect on the HSPCs but a mechanism-based result of continued blockade of 
HSPC proliferation that decreases the production of new blood cells. In contrast, we have 
shown that a brief and transient period of CDK4/6 inhibition by G1T28 does not have 
lingering myelosuppressive effect.
The current study extends earlier work on chemotherapy-induced acute myelosuppression 
(17) by showing beneficial effects after multiple cycles of chemotherapy treatment that are 
long-lasting, transplantable, and associated with enhanced HSC function. Unlike lineage-
specific strategies used in the clinic to manage acute chemotherapy-induced 
myelosuppression (such as transfusions and G-CSF/EPO), CDK4/6i-induced PQ protects all 
blood cell lineages. Moreover, unlike growth factor treatment, which enhances short-term 
blood cell count recovery at the cost of increasing the risk of leukemia and BM failure (6–9), 
a CDK4/6i-induced G1 arrest coincident with chemotherapy administration preserves HSC 
function. Therefore, CDK4/6i-mediated PQ provides the additional benefit of ameliorating 
the long-term sequelae of cytotoxic agents.
Chemotherapy-associated late BM toxicity results from therapy-induced damage and 
premature exhaustion of HSCs. Cytotoxics not only can cause direct damage to activated 
HSCs, but also can induce functional attrition of HSCs indirectly through a process of 
proliferative exhaustion (Fig. 4, 5 and (22)). This HSC cell intrinsic damage leads to a 
reduction of long-term multilineage reconstitution potential as well as myeloid-biased 
differentiation. Reduced long-term HSC function is clinically manifested in cancer survivors 
as persistent cytopenias, high rates of secondary leukemia and MDS, reduced T cell 
production and decreased cellular immunity. In the current study, we showed that PQ can 
attenuate chemotherapy-induced HSC exhaustion and lineage bias by directly modulating 
the cell cycle of rapidly proliferating activated HSCs at the time of exposure to cytotoxic 
agents, as well as by indirectly protecting quiescent HSCs by reducing their proliferative 
burden. Although we were unable to directly assess the effect of CDK4/6 inhibition on the 
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incidence of chemotherapy-induced secondary leukemia, we provide evidence that a G1T28-
induced G1 arrest will attenuate most aspects of chemotherapy-induced late BM toxicity.
Beyond reducing late toxicity, the preservation of HSC function would be expected to 
increase rates of tumor response and long-term cure through a variety of mechanisms. First, 
dose density and intensity are important predictors of tumor response in several RB-deficient 
tumors (such as SCLC (42) and triple negative breast cancer (TNBC) (43)), and reduced 
HSC exhaustion would prevent the dose reductions and treatment delays mandated by the 
persistent cytopenias that commonly occur in patients after multiple cycles of therapy. 
Moreover, by reducing HSC myeloid bias and thereby preserving T cell production, this 
approach could be ‘immune sparing’. An extensive clinical literature suggests that 
treatment-related lymphopenia is associated with worsened outcome in several types of 
cancer (44). A preservation of cellular immunity could be especially important in patients 
who will later receive immune checkpoint inhibitors that induce anti-tumor immunity 
through the activation of T cells.
A limitation of the PQ approach is that a CDK4/6i-induced G1 arrest at the time of 
chemotherapy administration could protect tumor cells in addition to normal HSPCs (11, 
16). Therefore, it will be important to limit this approach to patients whose cancer 
proliferates independently of CDK4/6 activity. However, it is worth noting that CDK4/6-
independent cancers are not rare: it is estimated in the US alone that there are 300,000 new 
cases of cancers annually whose proliferation does not depend on CDK4/6 activity (16). 
Several molecular lesions would be expected to render a cancer CDK4/6-independent, the 
best described of which is inactivation of the RB protein (15, 17, 45, 46). RB1 is genetically 
inactivated in ~11% of human cancers (15), including virtually 100% of SCLCs (47) and at 
high frequency in TNBCs (48) as well as advanced carcinomas of the prostate (49) and 
bladder (50). Likewise, functional inactivation of RB through expression of the E7 
oncoprotein of human papilloma virus is common in squamous malignancies of the head and 
neck, anus, and cervix (51). Finally, we believe that an even larger fraction of cancers that 
retain RB expression are functionally deficient in RB through high-level activation of 
CDK2, which phosphorylates RB, by mechanisms that do not depend on CDK4/6 activity. 
For example, direct cyclin E amplification has been reported at moderate frequency (>20%) 
in several human solid tumors (TNBC, ovarian carcinoma, advanced prostate, and bladder 
cancer)(52). Further evidence for this notion comes from Novartis Cell Line Encyclopedia 
screens, which have shown that the vast majority of RB-expressing human cell lines are 
highly resistant to palbociclib (EC50 >2 µM), and therefore likely to be CDK4/6 independent 
(15). Therefore, even though CDK4/6i-mediated protection of normal HSPCs will not 
benefit all cancer patients, it offers a potential means to address debilitating short- and long-
term side effects of cytotoxic chemotherapy in a large number of patients with CDK4/6 
independent cancer.
Another limitation of this work is the schedule-dependent nature of this approach. We have 
shown that optimal protection is achieved when the period of HSPC G1 arrest overlaps with 
the in vivo biological effects of chemotherapy, but not for a longer or shorter period. If the 
period of growth arrest is too short, HSPCs re-enter the cell cycle in the setting of unrepaired 
DNA damage, causing increased myelosuppression. Likewise, an overly long period of PQ 
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prolongs count nadirs after chemotherapy. Therefore, the safe use of this approach in 
patients requires the careful timing of HSPC arrest relative to the effective half-life of the 
chemotherapy agents. These concerns can be largely addressed through the use of an agent 
like G1T28, with an IV formulation and a relatively short pharmacologic half-life, allowing 
for precise control of the period of HSPC cell cycle arrest.
In summary, we have shown precise control of human and murine HSPC proliferation using 
a small moleculeCDK4/6 inhibitor, G1T28. By using this agent to induce a transient cell 
cycle arrest at the time of exposure to cytotoxics, we have shown long-lasting and cell-
intrinsic protection of murine HSCs from chemotherapy-induced exhaustion. We also 
demonstrated that G1T28 is well tolerated after IV administration in healthy human 
volunteers and has robust pharmacodynamic activity in inducing transient and reversible cell 
cycle arrest of BM HSPCs, suggesting that CDK4/6i-induced PQ is feasible in humans. 
Because G1T28 is currently undergoing testing in this fashion in patients with SCLC 
(NCT02499770 and NCT02514447) and metastatic triple negative breast cancer 
(NCT02978716), it will be possible to determine if PQ similarly benefits human HSCs. Such 
an effect would be expected to increase chemotherapy efficacy as well as reduce late toxicity 
such as secondary leukemia and MDS in a large fraction of patients receiving cytotoxic 
chemotherapy.
MATERIALS AND METHODS
Study design
The preclinical portion of the current study aimed to determine whether transient G1 cell 
cycle arrest induced by pharmacological CDK4/6 inhibition could attenuate the late 
hematopoietic toxicity of cytotoxic chemotherapy. The well-characterized murine model of 
5FU-induced myelosuppression was used to assess the BM protective effect of G1T28. The 
effect of G1T28 on 5FU-induced HSC exhaustion was assessed by a variety of approaches 
including serial competitive BM transplantation. The data presented in this study reflect 
multiple independent experiments performed on separate days using different mice and 
contain more than 3 biological replicates. No statistical methods were used to predetermine 
the sample size. No data or outliers were excluded from our analyses. Age and gender-
matched mice were randomly treated with vehicle or the test compounds, and lethally 
irradiated mice were randomly assigned as BM transplantation recipients of variously 
treated donors. The investigators were not blinded during sample allocation or result 
analysis. The end point for the survival assay was determined as loss of more than 20% of 
peak body weight and/or deterioration of body condition. The extent of PB donor chimerism 
in BM transplantation recipients was monitored for more than 16 weeks to assess long-term 
multi-lineage reconstitution potential.
The clinical portion of the current study aimed to assess the safety, pharmacokinetics, and 
pharmacodynamics of IV administered G1T28 in healthy human volunteers. It was designed 
as a single-center; single-dose first-in-human study (NCT02243150), including a double-
blind, randomized, placebo-controlled (3:1 G1T28 vs. placebo administered as a 30 minute 
IV infusion), SAD part in six 4-8 subject cohorts, and an open-label 12 subject cohort to 
confirm the BED. The study followed a Continual Reassessment Method (CRM) design, 
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informed by the accrued safety experience throughout the study. Dose escalation between 
cohorts and the expansion from 4- to 8-subject cohorts were determined by the Safety 
Monitoring Committee (SMC) based on available safety, PK, and PD data. Up to a 100% 
dose escalation was allowed between cohorts, if supported by the available safety, PK, and 
PD data. Dose escalation was planned to continue until the SMC deemed that the BED had 
been reached or the criteria for halting dose escalation had been met. Dose escalation was to 
be halted in the following situations: occurrence of drug-related treatment-emergent ≥ Grade 
2 non-hematologic adverse events (AEs) or ≥ Grade 3 hematologic AEs in 2 or more 
subjects in a given cohort, ≥ Grade 3 non-hematologic AEs or ≥ Grade 4 hematologic AEs in 
a single subject in a given cohort, or a recommendation to halt dose escalation by the 
Principal Investigator. Based on preclinical PK/PD modeling and available safety, PK, and 
PD data from cohorts 1-6, 12 subjects were enrolled in Cohort 7 to confirm the BED. All 12 
subjects enrolled in cohort 7 had a single BM aspirate obtained at various time points 
relative to IV dosing of G1T28 to directly measure the effect of G1T28 on BM HSPC 
proliferation. The protocol and informed consent were reviewed and approved by the 
Institutional Independent Ethics Committee, and the trial was conducted in accordance with 
the principles of the Declaration of Helsinki, in compliance with the International 
Conference on Harmonization E6 Guideline for Good Clinical Practice, and in compliance 
with the European Union Clinical Trial Directive. All subjects provided written informed 
consent.
Mice
Mice used in this study were housed in the AAALAC-accredited, specific-pathogen-free 
animal care facility operated by the Division of Laboratory Animal Medicine at the 
University of North Carolina in Chapel Hill. Mouse work was conducted in accordance with 
protocols approved by the Institutional Animal Care and Use Committee. C57BL/6NTac 
(CD45.2) and B6.SJL-Ptprca/BoyAiTac (CD45.1) mice were purchased from Taconic. 
B6;129S4-Gt(ROSA)26Sortm1(rtTA*M2)JaeCol1a1tm7(tetO-HIST1H2BJ/GFP)Jae/J (H2B-GFP;M2-
rtTA) double transgenic mice were purchased from Jackson Laboratory.
Cell isolation and flow cytometry
Murine BM cells were isolated by flushing the femurs, tibias, and pelvic bones using ice-
cold staining medium (1× Ca2+- and Mg2+-free Hank’s balanced salt solution (HBSS, 
Gibco) supplemented with 10 mM EDTA (Corning) and 2% heat-inactivated bovine serum 
(Gibco)) and filtered through 40 μm nylon mesh (Sefar). Splenocytes and thymocytes were 
isolated by crushing spleen or thymus tissue between two microscope slides followed by 
filtering through nylon mesh. The number of viable cells was determined by manually 
counting with a hemocytometer. To identify HSCs, LSK cells, and myeloid progenitors 
(MPs) by flow cytometry, BM cells were stained with antibodies against c-Kit (2B8, APC-
Efluor780, eBioscience), Sca-1 (E13-161.7, APC), CD48 (HM48-1, PerCP-Cy5.5), CD150 
(TC15-12F12.2, biotin), as well as FITC-conjugated antibodies against the following lineage 
markers: CD2 (RM2–5), CD3e (145–2c11), CD4 (GK1.5), CD5 (53–7.3), CD8a (53–6.7), 
B220 (RA3-6B2), Mac-1 (M1/70), Gr-1 (RB6-8C5), and Ter119 (TER-119). CD150 
staining was developed using PE-Cy7 conjugated streptavidin. Sometimes c-Kit expressing 
cells were magnetically enriched using anti-APC magnetic beads on the autoMACS system 
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(Miltenyi). To identify mature myeloid, erythroid, and B lineage cells, BM cells were 
stained with antibodies against Gr-1 (FITC), B220 (PerCP-Cy5.5), Ter119 (Alexa Fluor 
700), and Mac-1 (APC-Efluor 780, eBioscience). All antibody staining of live cells was 
carried out on ice for 1 hour. All primary and secondary antibodies were purchased from 
Biolegend unless otherwise indicated. Flow cytometry analysis of stained cells was 
performed on a customized LSR II 7-laser, 17-color flow cytometer (Becton-Dickinson), and 
recorded data were analyzed in BD FACSDiva 8.0.1, FlowJo 10.0.8, or FCS Express 5 Pro 
RUO software.
Murine HSPC cell cycle analysis by EdU incorporation assay
EdU-labeled murine BM cells and thymocytes were isolated and stained with primary 
antibodies as described above. The stained cells were then labeled with LIVE/DEAD 
Fixable Red Dead Cell Stain (Life Technologies) for 30 minutes, followed by fixation in 5% 
formalin for 10 minutes on ice and permeabilization in staining medium plus 0.1% saponin 
for 10 minutes at room temperature. EdU staining was performed in 0.1 M Tris-HCl (pH 
7.5), 1 mM CuSO4, 0.1 M ascorbic acid, and 5 μM Alexa Fluor 555 azide (Life 
Technologies) for 10 minutes at room temperature (53). Stained cells were washed twice 
with ice-cold staining medium, followed by incubation in secondary antibody and 2 μg/ml of 
4′, 6-diamidino-2-phenylindole (DAPI) for 30 minutes on ice before flow cytometry 
analysis.
In vivo G1T28 murine pharmacokinetic (PK) assay
For PK study after IP administration, four- to five-month-old female C57BL/6NHsd mice 
were given a single injection of 50 mg/kg or 100 mg/kg G1T28. For oral PK study, eight- to 
ten-week-old male CD1 mice were gavaged with 10, 50, or 100 mg/kg of G1T28. Blood was 
collected from treated mice via cardiac puncture at 5, 15, and 30 minutes or 1, 2, 4, 8, 12, 
18, 24, 36, and 48 hours after drug administration (3 mice/dose/time point). Plasma G1T28 
concentration was determined by LC-MS/MS as follows. Murine plasma samples were 
spiked with G1T28 and the corresponding D3 stable label internal standard (IS) followed by 
protein precipitation with acetonitrile. After precipitation, a portion of the organic layer was 
transferred to a 96-well plate, and the extract was chromatographed by reversed phase HPLC 
on an Allure PFP Propyl column with a mobile phase containing acetonitrile, water, 
ammonium formate and formic acid. G1T28 and D3 IS were detected by monitoring the 
precursor and product ions (m/z 447.2 → 336.2 for G1T28, m/z 450.2 → 339.4 for G1T28 
D3 IS) with a Sciex 4000 LC MS/MS system. Analyte-to-IS peak area ratios for the 
standards were used to create linear calibration curves with weighted (1/x2) least-squares 
regression analysis. The calibration range of the assay was 10 to 10,000 ng/mL with a 
sample volume of 20 µL of plasma. PK parameters on plasma G1T28 concentration were 
calculated in Watson (v7.3.0.01, Thermo Inc.).
In vivo G1T28 dose response and pharmacodynamic assay
To determine the dose response of various murine hematopoietic cell types to G1T28-
induced cell cycle arrest, 8- to 10-week-old female C57BL/6 mice were treated with a single 
dose of 0, 10, 25, 50, 100, or 150 mg/kg G1T28 by IP injection. Twelve hours later, each 
mouse was given a single IP injection of 10 mg/kg EdU and harvested 2 hours later. EdU 
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staining of BM cells and thymocytes was performed as described above. To determine the in 
vivo pharmacodynamics of G1T28 on murine hematopoietic cell proliferation, 8- to 10-
week-old female C57BL/6 mice were given a single IP injection of 50 or 100 mg/kg G1T28, 
followed by a single IP injection of 10 mg/kg EdU at 0.5, 1, 2, 4, 6, 12, 18, 24, 36, 48, 72, or 
168 hours later. BM cells and thymocytes were isolated 2 hours after EdU injection and 
stained as described above. To determine the effect of G1T28 on actively cycling HSCs, 8-
week-old female C57BL/6 mice were given a single IP injection of 150 mg/kg 5FU. 4 days 
later, half (n = 4) of the treated mice received a single IP injection of 100 mg/kg G1T28, and 
the other half (n = 4) received vehicle (50 mM citrate buffer) solution. Twelve hours later, 
each mouse was labeled with EdU for 2 hours. The frequency of EdU+ HSCs in each 
treatment group was determined as described.
5FU survival assay
Eight- to ten-week-old female C57BL/6 mice were given a single IP injection of 150 mg/kg 
5FU once every 7 or 10 days. G1T28 was given to a subset of 5FU-treated animals at 30 
minutes, 12 hours, and/or 24 hours before each 5FU treatment at 50 or 100 mg/kg dose by IP 
injection. Pegfilgrastim (250 μg/kg) was given to a subset of 5FU-treated animals 24 hours 
after each 5FU treatment by subcutaneous (SC) injection. Treated mice were monitored 
daily for body condition and/or weight loss, and the end point was determined as severe 
deterioration of body condition and/or loss of more than 20% of peak body weight.
Methylcellulose colony formation assay
C57BL/6 mice were orally gavaged with vehicle or 150 mg/kg of G1T28 30 minutes or 12 
hours before being treated with 150 mg/kg of 5FU. BM progenitor colony-formation assay 
was performed by plating 1 × 104, 3 × 104, or 6 × 104 unfractionated BM cells harvested at 
1, 2, or 4 days after 5FU into methylcellulose culture medium (Methocult GF M3434, 
StemCell Technologies). Hematopoietic colonies were counted after 8 – 9 days of culture at 
37°C in 5% CO2.
Serial 5FU treatment and competitive BM reconstitution assay
Eight-week-old female B6.SJL-Ptprca/BoyAiTac (CD45.1) mice were treated with 4 rounds 
of vehicle (1x phosphate buffered saline [PBS]) or 150 mg/kg 5FU at 3-week intervals. A 
subset of the 5FU-treated mice was given a single dose of 150 mg/kg G1T28 by oral gavage 
30 minutes before each 5FU injection or 2 doses of 250 μg/kg pegfilgrastim by SC injection 
at 24 and 48 hours after each 5FU treatment, and the remaining mice received vehicle (50 
mM citrate buffer (pH4.0) for gavaging and 0.1% bovine serum albumin in 1x PBS for SC 
injection) treatment. CBCs were analyzed 4, 7, 11, 14, 18, and 21 days after the last round of 
5FU treatment to assess the rate of hematologic recovery. Eight weeks after the last dose of 
5FU treatment, BM cells were harvested from the treated mice, and competitive long-term 
BM reconstitution assay was performed by transplanting 500,000 total BM cells (CD45.1+) 
from each donor, together with 500,000 competitor BM cells (CD45.2+, from 8-week-old 
C57BL/6 mice), into lethally irradiated 8-week-old female C57BL/6 (CD45.2+) recipients. 
Lethal irradiation was carried out using a Gammacell 40 Exactor Cesium137 γ-ray source 
(MDS Nordia) by giving two doses of 540 rads total body irradiation 2 hours apart. BM cells 
from each donor mouse were transplanted into 5 recipient mice, and 5 donors were 
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transplanted from each treatment group. PB was collected from the tail veins of recipient 
mice at 4-week intervals for at least 16 weeks after transplantation. To assess the frequency 
of donor cells in PB, red blood cells were subjected to ammonium-chloride potassium lysis 
(54), and remaining leukocytes were stained with antibodies against CD45.2 (104, FITC), 
CD45.1 (A20, APC-Efluor 780, eBioscience), B220 (PerCP-Cy5.5), Mac-1 (APC), CD3e 
(PE), and Gr-1 (PE-Cy7). Thirty two weeks after initial transplantation, BM cells were 
harvested from each primary recipient mouse and analyzed for donor cell contribution to 
each hematopoietic lineage. For HSC analysis, BM cells were stained with antibodies 
against lineage markers (FITC), c-Kit (APC-Efluor 780), Sca-1 (PE-Cy7), CD150 (PerCP-
Cy5.5), CD48 (PE), CD45.1 (BV421), and CD45.2 (Biotin, followed by streptavidin-Alexa 
Fluor 647). For analysis of mature myeloid, B, and T cells, BM cells were stained with 
antibodies against Mac-1 (APC-Efluor 780), Gr-1 (PE-Cy7), B220 (PerCP-Cy5.5), CD3 
(PE), CD45.2 (FITC), and CD45.1 (BV421). Secondary BM transplantation was performed 
by transplanting 1 × 107 total BM cells from each primary recipient into an individual 
lethally irradiated secondary recipient (CD45.2+). The frequencies of donor CD45.1+ cells in 
each blood lineage were monitored by analyzing the PB of secondary recipients at 4-week 
intervals for at least 16 weeks after transplantation.
H2B-GFP label dilution assay
To analyze the proliferation history of HSCs after 5FU and/or G1T28 treatment, adult 
homozygous H2B-GFP;M2rtTA mice were treated with 2 mg/ml doxycycline in drinking 
water for 6 weeks to label all HSCs. Two weeks after removing doxycycline, mice were 
given a single dose of vehicle or 150 mg/kg G1T28 by oral gavage 12 hours before vehicle 
or 150 mg/kg 5FU treatment. Four weeks after 5FU administration, BM cells were harvested 
and analyzed for H2B-GFP expression. Unfractionated BM cells were stained with 
antibodies against lineage markers (Biotin, followed by streptavidin-PE/Cy7), CD150 (PE), 
CD48 (PerCP-Cy5.5), c-Kit (APC-Efluor 780), and Sca-1 (APC). Curve fitting for HSC 
H2B-GFP label dilution data was performed using the proliferation analysis module in FCS 
Express 5 Pro RUO software.
Human study population and safety assessment
Eligible subjects included males and females 18-60 years of age with a body mass index of 
18 to 32 kg/m2 (inclusive) and a weight of at least 50 kg. The subjects had to be judged to be 
in good health based on medical history and physical examination including vital signs, 
electrocardiogram, and clinical laboratory results. Women of childbearing potential were 
determined to be in a nongravid state and had agreed to take appropriate precautions to avoid 
pregnancy from the study enrollment until 3 months after completion of the study. Male 
subjects with a female partner of childbearing potential were required to use a highly 
effective form of birth control during the study and for 3 months after completion of the 
study. Use of medications or herbal products within 14 days before the start of the study was 
not allowed. Use of investigational medications within 60 days of the start of the study was 
not allowed.
Safety and tolerability assessments consisted of monitoring AEs, clinical laboratory results, 
vital signs, 12‐lead electrocardiograms (ECG), and physical examination. Subjects were 
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admitted to the clinic on Day (-1) and remained in the clinic until all study procedures had 
been completed on Day 5. Subjects returned to clinic for further evaluation on Days 7, 10, 
and 14. The reporting period for serious adverse events (SAEs) began from the time that the 
subject provided informed consent up to and including the Day 14 follow‐up visit. AEs were 
recorded from the time of first dosing up to and including the Day 14 follow‐up visit, and all 
AEs had to be followed until they had resolved, returned to baseline, or it was deemed that 
further recovery was unlikely. Toxicity was assessed using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (CTCAE) v4.0 criteria.
Human PK study
G1T28 concentration in human plasma and urine was determined using a validated LC-
MS/MS assay. For assay validation, human plasma samples were spiked with G1T28 and the 
corresponding D3 stable label internal standard (IS), followed by protein precipitation using 
acetonitrile. A portion of the organic layer after protein precipitation was transferred to a 96-
well plate, and the extract was chromatographed by reversed phase HPLC on a Waters 
XBridge C18 (part #186003021) with a mobile phase containing acetonitrile, water, 
ammonium acetate and formic acid. G1T28 and the D3 IS were detected by monitoring the 
precursor and product ions (m/z 447 → 336 for G1T28, m/z 450 → 339 for G1T28 D3 IS) 
with a Sciex API 4000 LC-MS/MS system. Analyte-to-IS peak area ratios for the standards 
were used to create linear calibration curves with weighted (1/x2) least-squares regression 
analysis. The calibration range of the assay was 0.5 to 1,000 ng/mL, with a sample volume 
of 50 µL of plasma. The precision, accuracy, selectivity, and LLOQs of the assay were 
determined for G1T28; and the benchtop, freeze/thaw, and freezer stability of the analyte 
under the conditions of the assay were determined with appropriate QC samples. All of the 
assessments met the acceptance criteria established for a validated assay. Using this 
validated assay, plasma (cohorts 1-7) and urine concentrations (cohort 7) of G1T28 were 
determined with lower limits of quantitation of 0.5 ng/mL and 5.0 ng/mL in plasma and 
urine, respectively. Blood samples were collected before the dose and at multiple time points 
after the dose. Standard PK parameters were calculated using both a noncompartmental and 
a compartmental method (Phoenix WinNonlin 6.3).
Human BM proliferation assay
A single BM aspirate was obtained from all subjects enrolled in the BED cohort (cohort 7, 
192 mg/m2, N = 12) to determine the effect of G1T28 on the percentage of various BM 
progenitor lineages in the G0/G1 or S/G2/M phases of the cell cycle. Using flow cytometry, 
lineages were identified using the markers CD45, CD34, CD14, CD11b, CD71, and CD61, 
and the cell cycle phases were evaluated using DRAQ5 DNA dye. BM progenitor cell 
proliferation was measured before dosing (n = 5), 24 hours after G1T28 dosing (n = 3), or 32 
hours after G1T28 dosing (n = 4). Two BM samples (one before a dose and one at 32 hours 
after a dose) were heavily contaminated with peripheral blood, considered technically 
inadequate, and were removed from the cell cycle analysis data sets.
Statistical analysis
Statistical significance of differences between two sample groups was assessed using two-
tailed Student’s t-test in Graphpad Prism 6 after the similarities in data variance between 
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groups were determined using F-test. The survival analysis of mice after serial 5FU 
treatment was performed in Graphpad Prism 6 using log-rank test. Sample sizes for all data 
are given in each figure legend. Error bars represent SEM or SD as described in the figure 
legends. Unless otherwise indicated, a P-value less than 0.05 was considered statistically 
significant.
Demographic and safety data for each human subject were tabulated and summarized using 
descriptive statistics. Summary statistics (means, min-max, standard deviations, coefficients 
of variation) were calculated using noncompartmental and compartmental methods with 
WinNonlin software (V6.3, Pharsight) for the concentration versus time data at each 
sampling and for derived PK parameters. Comparisons of the proliferation of various human 
hematopoietic stem and progenitor subsets at baseline or after G1T28 treatment were made 
using two-tailed t-test with a P-value of 0.05.
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One Sentence Summary
The concomitant use of CDK4/6 inhibitors with cytotoxic agents may prevent 
chemotherapy-induced bone marrow exhaustion in cancer patients.
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Fig. 1. G1T28 induces transient, reversible G1 cell cycle arrest in both murine and human BM 
HSPCs
(A) Rate of murine BM HSC proliferation 12 hours after a single IP injection of the 
indicated doses of G1T28 (n = 5 mice/dose analyzed in 5 independent experiments, same for 
B and C). (B) Median effective dose (ED50) of G1T28 to inhibit the in vivo proliferation of 
the indicated murine hematopoietic cell types with identification scheme shown in fig. S1 
(LSK = Lin−Sca-1+c-Kit+ cells, MP = myeloid progenitors, E = erythroid, M = myeloid, B = 
B lymphocytes, T = T lymphocytes). (C) Relative proliferation rate of each murine 
hematopoietic cell type at maximum CDK4/6 inhibition, compared to untreated mice. (D) 
Rate of murine BM HSC proliferation at various time points after a single IP injection of 50 
or 100 mg/kg of G1T28 (n = 3-6 mice/dose/time point). (E) Mean plasma concentration 
curve of G1T28 after single dose IV administration in healthy human volunteers. (F, G) 
Frequency of total human BM cells (F) and HSC-enriched CD45dimCD34+CD38− BM cells 
(G) in S/G2/M phase of the cell cycle either before or at 24 and 32 hours after single dose of 
G1T28 treatment. Data were from Cohort 7 (BED) after single 192 mg/m2 dose of G1T28. 
Error bars represent SD in A-D and SEM in E-G. The statistical significance of differences 
between vehicle and G1T28 treated groups in A and D and between indicated groups in B, 
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C, and F was assessed using unpaired, two-tailed Student’s t-tests (*P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001).
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Fig. 2. Transient G1 arrest by G1T28 pretreatment accelerates hematologic recovery after single 
dose 5FU treatment
(A, B) Complete blood cell counts (A) and BM cellularity (B) at various time points after a 
single dose of 5FU with or without G1T28 pretreatment (n = 5-18 mice/treatment/time 
point). (C) Number of colony-forming cells (CFC) per femur 1 to 4 days after a single 
treatment with 5FU ± G1T28 (n = 4-11 mice/treatment/time point). Data represent mean ± 
SEM in A and mean ± SD in B and C. The statistical significance of differences between 
indicated groups was assessed using unpaired, two-tailed Student’s t-tests (*P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001).
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Fig. 3. G1T28 pretreatment protects mice from repeated doses of 5FU challenge
(A–D) Survival curves of mice that were treated with 5FU plus vehicle, G1T28, or 
pegfilgrastim at 7 (A) or 10 (B-D) day intervals. G1T28 was given 12 hours before 5FU in A 
and B, and either 30 minutes before, 24 hours before, or both in C. Pegfilgrastim was given 
24 hours after 5FU in (D). Numbers in parenthesis indicate median survival (d = day), and 
animal number (n) in each treatment group. Significance for the pairwise comparison to 5FU 
+ vehicle was calculated using the log-rank test in A, B, and D and Gehan-Breslow-
Wilcoxon test in C (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not 
significant).
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Fig. 4. G1T28-induced PQ protects HSCs from proliferative exhaustion
(A) Treatment and BM transplantation schematic. WBM, whole bone marrow cells (B-E) 
The percentage of donor-derived cells (CD45.1+) in total PB leukocytes (B), or myeloid cell 
(Mac1+, C), B lymphocyte (B220+, D), and T lymphocyte (CD3+, E) fractions 1 to 4 months 
after primary BM transplantation. 3-8 donor mice/treatment, 5 recipients/donor. Statistical 
significance of differences between treatment groups at 16 weeks after transplantation was 
assessed using one-way ANOVA with correction for multiple comparisons. (*, P < 0.05 
compared to control; †, P < 0.05 compared to 5FU + vehicle, ‡, P < 0.05 compared to 5FU + 
G1T28). (F) The percentages of donor-derived cells in total BM cells, HSCs, and major BM 
cell lineages 32 weeks after BM transplantation. 5 donor mice/treatment, 5 recipients/donor. 
Statistical significance was assessed by two-tailed Student’s t-test (*P < 0.05, **P < 0.01, 
***P < 0.001). Average donor cell reconstitution in B-F was calculated by first averaging the 
value of the 5 recipients from each donor, followed by calculating the mean of all donors. 
Error bars represent SEM.
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Fig. 5. Transient CDK4/6 inhibition protects long-term HSC function against serial 5FU 
treatment by reducing overall proliferative burden
(A) The percentage of donor-derived cells (CD45.1+) in total PB leukocytes or myeloid cell 
(Mac1+), B lymphocyte (B220+), and T lymphocyte (CD3+) fractions 1 to 4 months after 
secondary BM transplantation. Data represent the mean ± SEM from 20-22 mice per group. 
(B, C) Cumulative HSC proliferation after a single dose of 5FU ± G1T28 treatment as 
determined by H2B-GFP label retention 4 weeks after 5FU administration. Representative 
H2B-GFP label dilution histograms (and curve fitting) are shown in (B), with quantification 
in (C). Proliferation index (PI) indicates the average number of daughter cells generated 
from a single, originally labeled HSC by the time of analysis, such that Log2 (PI) equals the 
average number of HSC divisions. Data represent mean ± SD from 3-6 mice in 3 
experiments. Statistical significance was assessed by unpaired, two-tailed Student’s t-test 
(*P < 0.05, **P < 0.01, ***P < 0.001). div, division.
He et al. Page 27
Sci Transl Med. Author manuscript; available in PMC 2018 January 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
